The major companies in the therapeutic market are Roche, Novartis, and Eisai and for diagnostics, GE Healthcare and Eli Lilly are the major companies. The key manufacturers in the market are Abbvie Inc., AC Immune SA, Allergan PLC, Amarantus Bioscience Holdings, Anavex LifeSciences, Avid Radiopharmaceuticals, Axon Neuroscience, etc.
The Alzheimer's drugs market is anticipated to record a significant CAGR of 1.9% during the forecast period (2017-2021). Although the market for Alzheimer's disease treatments currently stands at USD 5 billion, the figure is expected to more than double, to reach USD 10.4 billion in 2021. The market is expected to be valued at around USD 6.4 billion by 2025, as the neurological disorder becomes more prevalent in the geriatric population and people live longer.
Latest Developments
While Alzheimer’s disease has no cure, only five prescription medicines have been approved by the US Food and Drug Administration (FDA) to treat the disease. The current diagnosis of Alzheimer's relies on documenting the mental decline. Blood biomarkers are expected to help in the detection of the early onset of Alzheimer’s, which would help in the treatment of the disease. Experts take help of biomarkers and several potential biomarkers are being studied for the early stages of Alzheimer's disease. The latest developments in the Alzheimer's drugs market have completely changed by the introduction of the disease-modifying therapies and diagnostic technologies. All the prescribed medications have been currently approved to treat Alzheimer’s in early-to-moderate stages, with a class of drugs that are called cholinesterase inhibitors.
Market Insights
The Alzheimer’s therapeutic market accounted for USD 5.7 billion in 2015, with a CAGR of 10.3%. Owing to drug patent expirations and many entrants entering the market, the market is expected to witness a slump by 2017. The market is anticipated to record growth, driven by the disease-modifying drugs and vast last-stage pipeline drugs. The prevalence of Alzheimer’s in the United States is almost 5 million. Moreover, owing to the increasing aging population, it is expected to grow further, globally. The maximum incidence of this disease is recorded in the United Kingdom, where more than 520,000 people are diagnosed with Alzheimer's. The increasing ageing population drives the Alzheimer’s disease diagnostic and therapeutic market. North America held the largest share in the global Alzheimer’s disease diagnostic market in 2015. Europe was the second-largest market for Alzheimer’s disease diagnostics. Asia Pacific is expected to record the fastest growth of the Alzheimer’s disease diagnostic market in the coming years.

By therapeutic, the market has been segmented into cholinesterase inhibitors, biomarkers, and NMDA receptor antagonists. By diagnostic, the market has been segmented into brain imaging and blood. The major drugs in the Alzheimer’s market are Nameda, Aricept, and Exelon and the expected decline of the market is due to patent expirations of Namenda and Aricept. The Alzheimer’s disease market is further segmented by geographical region into North America (which includes the United States and Canada), Latin America (Brazil, Argentina, Colombia), Europe (United Kingdom, France, Germany, Italy), Asia-Pacific (Japan, China, India, and Australia) and the Middle East & Africa (Saudi Arabia, UAE, Qatar, and South Africa). The market in Asian countries may increase due to Edaravone, a promising drug for this indication. The major companies in the therapeutic market are Roche, Novartis, and Eisai. On the other hand, the major companies in the diagnostic market are GE Healthcare and Eli Lilly.
About Mordor Intelligence
Mordor Intelligence is a market intelligence and business advisory firm. The company operates in the business of industry analysis and consulting, in over 16 verticals. In today’s fast-paced and competitive business environment, every customer has unique information requirements. With an eye to such requirements, Mordor offers custom market intelligence and advisory services, along with syndicated reports, to help customers gain an edge over the competition. The company has successfully catered to over 500 (40% of whom are Fortune 500) clients, since 2013.
For more information, write to us at: [email protected]